Brought to you by 
Cytyc withdraws acquisition of Digene
05 Sep 2002
Executive Summary
Cytyc, manufacturer of the Thin Prep Pap Test has agreed to acquire Digene (gene based diagnostics) in a stock and cash deal valued at approximately $553.9mm. Cytyc will pay $76.9mm in cash and issue 23.5mm common shares for all outstanding Digene equity.
Deal Industry
- In Vitro Diagnostics
-
In Vitro Diagnostics
- Molecular Diagnostics & Genetic Testing
-
Biotechnology
-
Drug Discovery Tools
- Genomics-Proteomics
-
Drug Discovery Tools
Deal Status
- Withdrawn
Deal Type
-
Acquisition
- Full Acquisition
- Includes Contract
- Intra-Biotech Deal
- Payment Includes Cash
- Payment Includes Stock
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Cytyc withdraws acquisition of Digene
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice